Mrs
Dr
Miss
Ms
Prof
Printer Friendly
Printed from http://www.researchandmarkets.com/reports/1464090
University of Minnesota - Developmental Therapeutics Review - Q4 2010
Description:
University of Minnesota – Developmental Therapeutics Review – Q4 2010
Summary
Global Market Direct’s pharmaceuticals report, “University of Minnesota – Developmental Therapeutics Review – Q4 2010” provides data on the institute’s research and development focus. The report includes information on therapeutics under development, complete with latest updates, and features on discontinued projects (if applicable).
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, institute’s website, and featured press releases, both from institute and industry-specific third party sources, put together by Global Markets Direct’s team of industry experts.
Scope
- Review of therapeutics under development by University of Minnesota.
- Overview of products under development across various therapy areas.
- Coverage of therapeutic molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of University of Minnesota with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of University of Minnesota’s therapeutic products in the last quarter.
- Latest news and deals relating to the products.
Reasons to buy
- Identify new drug targets and therapeutic classes in University of Minnesota’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying opportunities to fill portfolio gaps.
- Evaluate University of Minnesota’s position with total access to a detailed information on its therapeutic products development.
- Assess the growth potential of University of Minnesota in its therapy areas of focus.
- Exploit collaboration and partnership opportunities with University of Minnesota.
- Avoid Intellectual Property Rights related issues.
Summary
Global Market Direct’s pharmaceuticals report, “University of Minnesota – Developmental Therapeutics Review – Q4 2010” provides data on the institute’s research and development focus. The report includes information on therapeutics under development, complete with latest updates, and features on discontinued projects (if applicable).
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, institute’s website, and featured press releases, both from institute and industry-specific third party sources, put together by Global Markets Direct’s team of industry experts.
Scope
- Review of therapeutics under development by University of Minnesota.
- Overview of products under development across various therapy areas.
- Coverage of therapeutic molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of University of Minnesota with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of University of Minnesota’s therapeutic products in the last quarter.
- Latest news and deals relating to the products.
Reasons to buy
- Identify new drug targets and therapeutic classes in University of Minnesota’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying opportunities to fill portfolio gaps.
- Evaluate University of Minnesota’s position with total access to a detailed information on its therapeutic products development.
- Assess the growth potential of University of Minnesota in its therapy areas of focus.
- Exploit collaboration and partnership opportunities with University of Minnesota.
- Avoid Intellectual Property Rights related issues.
Contents:
List of Tables
List of Figures
University of Minnesota Snapshot
University of Minnesota Overview
Key Information
Key Facts
University of Minnesota – Research and Development Overview
Key Therapeutic Areas
University of Minnesota – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
University of Minnesota – Pipeline Products Glance
University of Minnesota – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
University of Minnesota Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
University of Minnesota – Drug Profiles
Alfuzosin Hydrochloride for Ureteral Stent Discomfort
Product Description
Mechanism of Action
R&D Progress
Bupropion + Naltrexone
Product Description
Mechanism of Action
R&D Progress
Chloroquine
Product Description
Mechanism of Action
R&D Progress
Nicardipine
Product Description
Mechanism of Action
R&D Progress
Proleukin + Anti-HIV Therapy
Product Description
Mechanism of Action
R&D Progress
Anti-thymocyte globulin + Cyclophosphamide + Fludarabine + Methylprednisolone + Filgrastim + Cyclosporine + Stem Cell Transplant
Product Description
Mechanism of Action
R&D Progress
Anti-Thymocyte Globulin + Cyclosporine + Everolimus
Product Description
Mechanism of Action
R&D Progress
Carvedilol Phosphate + Lisinopril
Product Description
Mechanism of Action
R&D Progress
Exenatide
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Busulfan + Mycophenolate Mofetil + Cyclosporine + Fludarabine + Melphalan + Umbilical Cord Blood Stem Cell Transplantation
Product Description
Mechanism of Action
R&D Progress
Fludarabine + Cyclophosphamide + Radiation + NK Cells
Product Description
Mechanism of Action
R&D Progress
hOKT3?1 + Sirolimus
Product Description
Mechanism of Action
R&D Progress
MGA031 + Sirolimus + Tacrolimus
Product Description
Mechanism of Action
R&D Progress
N-Acetyl Cysteine + Naltrexone
Product Description
Mechanism of Action
R&D Progress
Naltrexone
Product Description
Mechanism of Action
R&D Progress
Raptiva + Sirolimus
Product Description
Mechanism of Action
R&D Progress
Topotecan + Bevacizumab
Product Description
Mechanism of Action
R&D Progress
Triamcinolone Acetonide for Alopecia Areata
Product Description
Mechanism of Action
R&D Progress
Valacyclovir in Infectious Mononucleosis
Product Description
Mechanism of Action
R&D Progress
Valomaciclovir
Product Description
Mechanism of Action
R&D Progress
Varenicline
Product Description
Mechanism of Action
R&D Progress
Intravenous Topiramate
Product Description
Mechanism of Action
R&D Progress
Lenalidomide + Liposomal Doxorubicin
Product Description
Mechanism of Action
R&D Progress
University of Minnesota – Pipeline Analysis
University of Minnesota – Pipeline Products by Therapeutic Class
University of Minnesota Pipeline Products By Target
University of Minnesota – Pipeline Products by Route of Administration
University of Minnesota – Pipeline Products by Molecule Type
University of Minnesota - Dormant Projects
University of Minnesota – Locations And Subsidiaries
Head Office
Recent Developments
Financial Deals Landscape
University of Minnesota, Deals Summary, 2004 to 2010
University of Minnesota Detailed Deal Summary
Asset Finance
University of Minnesota Receives Grant For Biomass Power Project, U.S.
Licensing Agreements
Celladon Enters Into A License And Research Agreement With University of Minnesota
Imagenetix Enters Into A Licensing Agreement With University Of Minnesota
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Ordering:
Order Online - visit http://www.researchandmarkets.com/reports/1464090
Order by Fax - using the order form below
Order By Post - print the order form below and send to
Order by Fax - using the order form below
Order By Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Page 1 of 2
Printed Thursday, June 20, 2013
1:55:49 AM
1:55:49 AM
Fax order form
To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net
Order information
Please verify that the product information is correct and select the format you require.
Product name
University of Minnesota - Developmental Therapeutics Review - Q4 2010
Web Address
http://www.researchandmarkets.com/reports/1464090
Office Code
OC8DIQQLTPNRQU
Report Formats
Please enter the quantity of the report format you require.
| Format | Quantity | Price |
|---|---|---|
| Electronic (PDF) - Single User |
|
EUR 382 |
| Electronic (PDF) - Site License |
|
EUR 765 |
| Electronic (PDF) - Enterprisewide |
|
EUR 1,147 |
Contact information
Please enter all the information below in block capitals.
Title:
Mr
Mrs
Dr
Miss
Ms
Prof
Mrs
Dr
Miss
Ms
Prof
First Name:
Last Name:
Email Address:
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:
Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
Page 2 of 2
Printed Thursday, June 20, 2013
1:55:49 AM
1:55:49 AM
Payment information
Please indicate the payment method you would like to use by selecting the appropriate box.
Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder's Name:
Cardholder's Signature:
Expiry Date:
/
Card Number:
CVV Security Code:
Issue date:
/ (Diners Club only)
Pay by Check:
Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Pay by Wire Transfer:
Please transfer funds to:
Account Number:
83313083
Sort Code:
98-53-30
Swift Code:
ULSBIE2D
IBAN Number:
IE78ULSB98533083313083
Bank Address:
Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:
Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp